Acquisition Press Release

Scaling Silene Biotech’s DTC Stem‑Cell Preservation through Physician Partnerships

1. Opt‑In Rate Doubled to 80%

2. 2,000 Customers & $1.1M in Revenue

3. Sustained 10% Month‑Over‑Month Growth

Background

Silene Biotech pioneered a novel direct‑to‑consumer (DTC) stem‑cell preservation service—freezing healthy cells today to enable future regenerative therapies. While early adopters (biohackers and tech innovators) embraced the concept, broader growth hinged on capturing the “baby boomer” market, a demographic that relies on physician guidance for medical decisions.

Challenge

• Physician Trust Barrier: Baby boomer patients needed credible medical endorsement before opting in.

• Knowledge Gap: Both physicians and patients lacked awareness of stem‑cell collection benefits and regenerative‑medicine potentials.

• Scalability Constraints: Initial funding and MVP traction couldn’t sustain long‑term growth without a scalable go‑to‑market (GTM) model.

Solution

1. Physician‑First GTM Strategy

   • Conducted 50+ exploratory physician interviews in Los Angeles and San Francisco to uncover value levers.

   • Partnered with SpectraCell (via physician referrals) to integrate their new Telomere test—delivering “biological age” data alongside cell‑storage.

2. Service Repackaging & Branding

   • Launched StemFreeze: an approachable, single‑brand offering combining stem‑cell preservation, cell‑age analysis, and telemedicine consultation.

   • Deployed a white‑glove, mobile phlebotomy “concierge” to improve access and patient convenience.

3. Channel Partnerships and Narrative

   • Secured Bloodworks Northwest and leading West Coast physician champions as distribution partners.

   • Co‑developed educational materials aimed at both physicians (CE‑accredited webinars) and patients (easy‑to‑digest infographics).

Results & Key Metrics

1. Opt‑In Rate Doubled to 80%By refining messaging and leveraging physician referrals, donor opt‑in rose from 40% to over 80% in under 24 months—unlocking a reliable, high‑conversion funnel.

2. 2,000 Customers & $1.1M in RevenueThrough channel partnerships, Silene Biotech signed 2,000 paying customers and generated $1.1 million in subscription revenue within three years, directly contributing to its acquisition.

3. Sustained 10% Month‑Over‑Month GrowthIntroducing the telomere‑based analysis and telemedicine service drove consistent 10% MoM revenue growth, elevating average contract value by $200 per customer and delivering a new $30K/mo revenue stream within 18 months.

Conclusion

By shifting from a pure DTC approach to a physician‑endorsed, B2B2C model, Silene Biotech not only cracked the baby‑boomer market but also built a scalable, high‑value service portfolio—culminating in a strategic acquisition less than three years after launch.